Výsledky vyhledávání - "Yukari Hoshina"

Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Masakazu Abe, Yuichiro Ohe, Osamu Tokuyama, Hideaki Mizutani, Michiru Sakurai, Koki Mizukami, Daisuke Takei, Kazuhisa Nakashima, Yukari Hoshina, Hironobu Hashimoto, Takuhiro Yamaguchi, Noboru Yamamoto, Yasuhiko Sakata, Masahiko Nakao, Takako Yanai Takahashi, Sadamoto Zenda, Satoru Iwasa, Yosuke Uchitomi

Publikováno v: The Lancet Oncology. 21:242-249

Summary Background Olanzapine 10 mg added to standard antiemetic therapy including aprepitant, palonosetron, and dexamethasone has been recommended for the prevention of chemotherapy-induced nausea and vomiting. Guidelines suggest that a dose reducti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ca620a723224e35baee8d02b3d82dc1
https://doi.org/10.1016/s1470-2045(19)30678-3

Zobrazit plný text záznamu

Trial in progress: A phase I trial of dual EZH 1/2 inhibitor valemetostat tosylate (DS-3201b) in pediatric, adolescent, and young adult patients with malignant solid tumors

Autor: Ayumu Arakawa, Hitoshi Ozawa, Akihiro Hirakawa, Ryo Sadachi, Yukari Hoshina, Sawako Tomatsuri, Yoshimasa Saito, Reiko Makihara Ando, Keita Terashima, Kenichi Nakamura, Chitose Ogawa

Publikováno v: Journal of Clinical Oncology. 40:TPS10059-TPS10059

TPS10059 Background: Enhancer of zeste homolog enzymes (EZH1 and EZH2) form parts of the polycomb repressive complex 2 and regulate gene expression by catalyzing the tri-methylation of lysine 27 residue of histone H3. SMARCB1/INI1 is one of the core

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e340b0bdbdc6b420fcb0da1b5a2e18cb
https://doi.org/10.1200/jco.2022.40.16_suppl.tps10059

Zobrazit plný text záznamu

Olanzapine 5mg in Combination with Standard Antiemetic Therapy for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Cisplatin-Based Chemotherapy (J-FORCE): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial

Autor: Yasuhiko Sakata, Kazuhisa Nakashima, Michiru i Sakura, Takako Yanai, Yukari Hoshina, Yuichiro Ohe, Takuhiro Yamaguchi, Masakazu Abe, Noboru Yamamoto, Osamu Tokuyama, Sadamoto Zenda, Hironobu Hashimoto, Koki Mizukami, Yosuke Uchitomi, Satoru Iwasa, Masahiko Nakao, Daisuke Takei, Hideaki Mizutani

Publikováno v: SSRN Electronic Journal.

Background: Olanzapine 10 mg added to standard antiemetic therapy, including aprepitant, palonosetron, and dexamethasone, has been recommended for the prevention of chemotherapy-induced nausea and vomiting. Guidelines suggest that a dose reduction to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d8eeff2a0768ccf12d8d85f26b0e4d04
https://doi.org/10.2139/ssrn.3414429

Zobrazit plný text záznamu

A randomized, double-blind, placebo-controlled phase III trial evaluating olanzapine 5 mg combined with standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy: J-FORCE Study

Publikováno v: Journal of Clinical Oncology. 37:11503-11503

11503 Background: Olanzapine (OLZ) 10 mg added to standard antiemetic therapy including aprepitant (APR), palonosetron (PALO), and dexamethasone (DEX) has been recommended for the prevention of chemotherapy-induced nausea and vomiting (CINV) caused b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::72c3655177ee5cb43c89e782065a096d
https://doi.org/10.1200/jco.2019.37.15_suppl.11503

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání